Imatinib mesylate (STI571) prevents the mutator phenotype of Bcr-Abl in hematopoietic cell lines

Leukemia Research

Volumn 28, Issue 4, 2004, Pages 405-408

  Van Der Kuip, Heiko ^a   Moehring, Alexandra ^a   Wohlbold, Lara ^a   Miething, Cornelius ^c   Duyster, Justus ^c   Aulitzky, Walter E ^b  

^a DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^b ROBERT BOSCH HOSPITAL   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Bcr Abl kinase; HPRT; Imatinib mesylate (STI571); Mutator phenotype

Indexed keywords

BCR ABL PROTEIN; IMATINIB; PHOSPHOTRANSFERASE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; GENE DELETION; GENETIC STABILITY; HEMATOPOIETIC CELL; MOUSE; MUTATION RATE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN INDUCTION; PROTEIN PROTEIN INTERACTION;

EID: 1042289336     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2003.08.012     Document Type: Article

References (12)

1. Deutsch E., Dugray A., AbdulKarim B., Marangoni E., Maggiorella L., Vaganay S.et al. BCR-ABL down-regulates the DNA repair protein DNA-PKcs. Blood. 97:2001;2084-2090.
2. Canitrot Y., Lautier D., Laurent G., Frechet M., Ahmed A., Turhan A.G.et al. Mutator phenotype of BCR-ABL transfected Ba/F3 cell lines and its association with enhanced expression of DNA polymerase beta. Oncogene. 18:1999;2676-2680.
3. Klucher K.M., Lopez D.V., Daley G.Q. Secondary mutation maintains the transformed state in BaF3 cells with inducible BCR/ABL expression. Blood. 91:1998;3927-3934.
4. Slupianek A., Schmutte C., Tombline G., Nieborowska-Skorska M., Hoser G., Nowicki M.O.et al. BCR/ABL regulates mammalian RecA homologs, resulting in drug resistance. Mol. Cell. 8:2001;795-806.
5. Buchdunger E., Zimmermann J., Mett H., Meyer T., Muller M., Druker B.J. et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 56:1996;100-104.
6. Druker B.J., Tamura S., Buchdunger E., Ohno S., Segal G.M., Fanning S.et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 2:1996;561-566.
7. Druker B.J., Talpaz M., Resta D.J., Peng B., Buchdunger E., Ford J.M.et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344:2001;1031-1037.
8. Bai R.Y., Ouyang T., Miething C., Morris S.W., Peschel C., Duyster J. Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway. Blood. 96:2000;4319-4327.
9. van der Kuip H., Goetz A.W., Miething C., Duyster J., Aulitzky W.E. Adhesion to fibronectin selectively protects Bcr-Abl+ cells from DNA damage-induced apoptosis. Blood. 98:2001;1532-1541.
10. Salloukh H.F., Laneuville P. Increase in mutant frequencies in mice expressing the BCR-ABL activated tyrosine kinase. Leukemia. 14:2000;1401-1404.
11. Brain J.M., Saksena A., Laneuville P. The kinase inhibitor STI571 reverses the Bcr-Abl induced point mutation frequencies observed in pre-leukemic P190Bcr-Abl transgenic mice. Leukemia Res. 26:2002;1011-1016.
12. Kantarjian H., Sawyers C., Hochhaus A., Guilhot F., Schiffer C., Gambacorti-Passerini C.et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N. Engl. J. Med. 346:2002;645-652.